Breaking News
Investing Pro 0
🚨 Our Pro Data Reveals the True Winner of Earnings Season Access Data

Merck Soars After Potential Covid Drug Shows Lower Risk of Hospitalization, Death

Stock Markets Oct 01, 2021 07:53AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters.
 
MRK
-0.50%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

By Dhirendra Tripathi

Investing.com – Merck stock (NYSE:MRK) climbed more than 7% in Friday’s premarket trading after the company said trials of a drug it is developing against Covid showed reduced risks of hospitalization and deaths.

If approved, molnupiravir, the drug, could be the world’s first oral antiviral medicine for Covid, the company said in a note. Merck plans to seek emergency use authorization in the U.S. as soon as possible.

The company said the drug demonstrated consistent efficacy across viral variants Gamma, Mu and Delta, the most infectious of the lot.

The company is jointly developing the drug with Ridgeback Biotherapeutics.

The drug was administered to 775 patients in a phase-3 trial and at the time of the decision to stop the recruitment based on the interim efficacy results, the company said the trial was approaching full recruitment of the phase 3 sample size of 1,550 patients.

Eligibility criteria required that all patients had laboratory-confirmed mild-to-moderate COVID-19, with symptom onset within 5 days of study randomization. All patients were required to have at least one risk factor associated with poor disease outcome at study entry

Merck expects to produce 10 million courses of treatment by the end of 2021, with more doses expected to be produced in 2022. It will supply approximately 1.7 million courses to the U.S. government under an existing agreement, assuming all the approvals are in place.

Merck Soars After Potential Covid Drug Shows Lower Risk of Hospitalization, Death
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Comments (2)
Eero Rintala
Eero Rintala Oct 01, 2021 11:11AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
this basicly same as ivermectin....
fenster fenster
fenster fenster Oct 01, 2021 9:58AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Vaxart, Vxrt stock is the first oral against covid ..afaik
Kelly Mayer
Kelly Mayer Oct 01, 2021 9:58AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
please... c19early.com
Josh Davis
Josh Davis Oct 01, 2021 9:58AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Kelly Mayer lol also dexamethasone was found be as or more effective but guess what thats a cheap drug that doesnt pad the pockets
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email